Three new partners have joined HGF across its offices in Europe, while Carpmaels & Ransford has made UPC-focused hires in Germany
The firm has added six practitioners in recent weeks as it takes measured steps to build its IP practice with a focus on trade secrets work
Daralyn Durie discusses the ‘amazing’ opportunity of working on an AI case, the value of celebrating women, and how to build the next wave of talent
The firm reported a small uptick in overall revenue and profit per equity partner, while its IP team secured notable life sciences victories
Paul Ainsworth, who secured a settlement for his client in a patent dispute, says the case shows why medical claims by dietary supplement companies can threaten IP rights
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents
Sheppard Mullin’s latest hires explain why the firm's industry expertise impressed them
Partner moves data from April and May showed the firm boosted its presence in California, while another firm expanded in Atlanta
The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the Danish company’s injunction application
The IP team at Morais Leitão discusses high-stakes litigation, strategic partnerships with clients, and bolstering cross-border expertise
Camilla Balleny, who spent a decade at Carpmaels & Ransford, will become the firm’s first head of patent litigation, Managing IP can reveal
Sponsored
Sponsored
-
Sponsored by Maiwald Intellectual PropertyKerstin Wolff and Tobias Matschke of Maiwald Intellectual Property examine a landmark Unified Patent Court decision on second medical use claims and compare it with Germany’s established approach to ‘skinny label’ products
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry
-
Sponsored by Bugnion SpAAndrea Delbarba and Claudia Finetti of Bugnion SpA explain how supplementary protection certificates extend pharmaceutical patent protection, the role of paediatric extensions, and recent Italian clarifications on fees and regulatory processes
-
Sponsored by Spoor & FisherDavid Cochrane of Spoor & Fisher South Africa explains the key updates under the act, which strengthens breeder protections while supporting vulnerable farmers and aligning with international norms
-
Sponsored by Maiwald Intellectual PropertyKerstin Wolff of Maiwald Intellectual Property examines the EU’s winding path towards the regulation of new genomic techniques, with a proposed patent ban remaining a key source of contention
-
Sponsored by CASThe emerging trends and strategic approaches in intellectual property search and analytics are outlined in a CAS article that suggests how chemical industry stakeholders can strengthen patent programmes, empower R&D teams, and gain competitive insight
MBIP principals Andy Mukherji and Ellen Reid discuss the firm’s combination with Jones Tulloch and reveal why younger firms stand to gain from AI demand
Lawyers at Linklaters analyse some of the key UPC trends so far, and look ahead to life beyond the transition period
A partner who joined Fenwick alongside two others explains what drew her to the firm and her hopes for growth in Boston
Griffith Hack’s Amanda Stark, one of our ‘Top 250 Women in IP’, explains how peer support from male colleagues is crucial, and reveals why the life sciences sector is thriving
Interviews; Exclusives
Interviews; Exclusives
Mary Till says she has been helping clients navigate policy questions, including staffing concerns at the office
Börge Seeger reveals the similarities between IP strategy and F1, and opines on bookshops, espresso machines, and late-night emails
Colleen Tracy James, who joined as co-chair of the life sciences patent litigation group a little over a year ago, reveals her thoughts on hiring associates and AI
Madeleine Kelly, the Australia-based IP firm’s new managing partner, discusses its new advisory offering, a promising fresh hire and changing market dynamics
Chad Landmon explains how he recruited a former life sciences litigation colleague to the firm and reveals one of the key clients that he brought over
Jeffrey Morton, who moved to Haynes Boone in May, says he's excited about what the firm can do in San Diego as it looks to bolster its life sciences offering
-
Weekly take: Why the EU must press ahead with unitary SPCs
The EU should press ahead with plans to introduce a unitary SPC and the UPC and EUIPO should play leading roles, says Jörg Thomaier at Bayer -
Weekly take: IP-trade demands will fail future generations
The bedaquiline case highlights why tools such as India’s pre-grant opposition mechanism are so important -
Weekly take: No harm in senators exploring patent alternatives
A proposed study into delinkage may not amount to much, and must be backed by strong evidence, but it can’t hurt to look into the issue -
Opinion: Indian domestic policy must match WTO stand on IP waivers
India has been both urging for vaccine waivers before the WTO and refusing compulsory licensing in the country, but it’s not helping anyone
Practitioners and law firms should keep their eyes peeled as the shortlist for our annual Awards is set to be released